TANG Jue, YAO Zhirong. Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 473-479. DOI: 10.12290/xhyxzz.2021-0747
Citation: TANG Jue, YAO Zhirong. Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 473-479. DOI: 10.12290/xhyxzz.2021-0747

Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis

Funds: 

National Natural Science Foundation of China 81874252

More Information
  • Corresponding author:

    YAO Zhirong, E-mail:yaozhirong@xinhuamed.com.cn

  • Received Date: November 13, 2021
  • Accepted Date: January 09, 2022
  • Available Online: May 12, 2022
  • Issue Publish Date: May 29, 2022
  • Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterized by intense pruritus. A satisfactory understanding of itch in AD has been proved difficult to reach and the relapsing itch is believed to be primarily a result of dysfunction of the skin barrier, dysregulation of the immune system and multiple environmental factors. Itch-scratch cycle exacerbates skin lesions, promotes inflammation and neurological disorders, and triggers the desire to continue scratching. The current methods of treatment for controlling AD pruritus symptoms include topical and systemic drugs. The exploration on the mechanisms of atopic pruritus has provided novel therapeutic targets, such as IL-4, IL-13, IL-31, JAK, IL-33. The new advances in the mechanism and treatment of itch in AD were systemically reviewed.
  • [1]
    Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis[J]. Nat Rev Dis Primers, 2018, 4: 1.
    [2]
    Shaw TE, Currie GP, Koudelka CW, et al. Eczema pre-valence in the United States: data from the 2003 National Survey of Children's Health[J]. J Invest Dermatol, 2011, 131: 67-73. DOI: 10.1038/jid.2010.251
    [3]
    Albrecht M, Dittrich AM. Expression and function of histamine and its receptors in atopic dermatitis[J]. Mol Cell Pediatr, 2015, 2: 16. DOI: 10.1186/s40348-015-0027-1
    [4]
    Bataille A, Leschiera R, L'Hérondelle K, et al. In Vitro Differentiation of Human Skin-Derived Cells into Functional Sensory Neurons-Like[J]. Cells, 2020, 9: 1000. DOI: 10.3390/cells9041000
    [5]
    Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1[J]. J Allergy Clin Immunol, 2014, 133: 448-460. DOI: 10.1016/j.jaci.2013.10.048
    [6]
    Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond[J]. Br J Dermatol, 2019, 180: 464-474. DOI: 10.1111/bjd.16934
    [7]
    Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch[J]. Cell, 2017, 171: 217-228. e13. DOI: 10.1016/j.cell.2017.08.006
    [8]
    Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013, 155: 285-295. DOI: 10.1016/j.cell.2013.08.057
    [9]
    Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview[J]. Exp Dermatol, 2002, 11: 12-24. DOI: 10.1034/j.1600-0625.2002.110102.x
    [10]
    Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. DOI: 10.1016/j.cell.2020.12.033
    [11]
    Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade[J]. J Allergy Clin Immunol, 1997, 99: 640-647. DOI: 10.1016/S0091-6749(97)70026-5
    [12]
    Tsagareli MG, Nozadze I, Tsiklauri N, et al. Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators: Respective Involvement of TRPV1 and TRPA1[J]. Neuroscience, 2020, 449: 35-45. DOI: 10.1016/j.neuroscience.2020.09.048
    [13]
    McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519: 237-241. DOI: 10.1038/nature14022
    [14]
    Chandran V, Coppola G, Nawabi H, et al. A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program[J]. Neuron, 2016, 89: 956-970. DOI: 10.1016/j.neuron.2016.01.034
    [15]
    Zhang H, Guo Y, Wang W, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis[J]. Allergy, 2011, 66: 420-427. DOI: 10.1111/j.1398-9995.2010.02493.x
    [16]
    Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis[J]. Allergy, 2015, 70: 887-896. DOI: 10.1111/all.12632
    [17]
    Mack MR, Kim BS. The Itch-Scratch Cycle: A Neuroim-mune Perspective[J]. Trends Immunol, 2018, 39: 980-991. DOI: 10.1016/j.it.2018.10.001
    [18]
    Uche LE, Gooris GS, Bouwstra JA, et al. Barrier Capability of Skin Lipid Models: Effect of Ceramides and Free Fatty Acid Composition[J]. Langmuir, 2019, 35: 15376-15388. DOI: 10.1021/acs.langmuir.9b03029
    [19]
    Imai Y, Yasuda K, Nagai M, et al. IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils[J]. J Invest Dermatol, 2019, 139: 2185-2194. e3. DOI: 10.1016/j.jid.2019.04.016
    [20]
    Smith L, Gatault S, Casals-Diaz L, et al. House dust mite-treated PAR2 over-expressor mouse: A novel model of atopic dermatitis[J]. Exp Dermatol, 2019, 28: 1298-1308. DOI: 10.1111/exd.14030
    [21]
    Skabytska Y, Kaesler S, Volz T, et al. The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments[J]. Semin Immunopathol, 2016, 38: 29-43. DOI: 10.1007/s00281-015-0544-y
    [22]
    Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progres-sive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis[J]. J Allergy Clin Immunol, 2012, 130: 1344-1354. DOI: 10.1016/j.jaci.2012.07.012
    [23]
    Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs[J]. Allergy, 2020, 75: 1582-1605. DOI: 10.1111/all.14318
    [24]
    Tsoi LC, Rodriguez E, Stölzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses[J]. J Allergy Clin Immunol, 2020, 145: 1406-1415. DOI: 10.1016/j.jaci.2019.11.047
    [25]
    Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms[J]. Proc Natl Acad Sci USA, 2009, 106: 11330-11335. DOI: 10.1073/pnas.0905605106
    [26]
    Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. DOI: 10.1016/j.cell.2020.12.033
    [27]
    Song S, Lee K, Lee YM, et al. Acute health effects of urban fine and ultrafine particles on children with atopic dermatitis[J]. Environ Res, 2011, 111: 394-399. DOI: 10.1016/j.envres.2010.10.010
    [28]
    中国医师协会皮肤科医师分会过敏性疾病专业委员会, 中华医学会皮肤性病学分会特应性皮炎研究中心, 中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识[J]. 中华皮肤科杂志, 2021, 54: 391-396.
    [29]
    Oyoshi MK, Larson RP, Ziegler SF, et al. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression[J]. J Allergy Clin Immunol, 2010, 126: 976-984. e9845. DOI: 10.1016/j.jaci.2010.08.041
    [30]
    Howell MD, Novak N, Bieber T, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis[J]. J Invest Dermatol, 2005, 125: 738-745. DOI: 10.1111/j.0022-202X.2005.23776.x
    [31]
    Hon KL, Tsang YC, Pong NH, et al. Patient acceptabi-lity, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema[J]. Hong Kong Med J, 2015, 21: 417-425.
    [32]
    Seo SR, Lee SG, Lee HJ, et al. Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis[J]. Acta Derm Venereol, 2017, 97: 957-958. DOI: 10.2340/00015555-2699
    [33]
    Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines[J]. J Clin Psychopharmacol, 2002, 22: 511-515. DOI: 10.1097/00004714-200210000-00012
    [34]
    Zhang X, Wu Z, Hayashi Y, et al. Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state[J]. J Neurosci, 2014, 34: 3013-3022. DOI: 10.1523/JNEUROSCI.3681-13.2014
    [35]
    Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC-14028 cream-a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase Ⅱb randomized trial[J]. Br J Dermatol, 2019, 180: 1030-1038. DOI: 10.1111/bjd.17455
    [36]
    Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults[J]. Dermatol Ther (Heidelb), 2017, 7: 493-505. DOI: 10.1007/s13555-017-0201-6
    [37]
    Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic derma-titis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389: 2287-2303. DOI: 10.1016/S0140-6736(17)31191-1
    [38]
    Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial[J]. JAMA Dermatol, 2020, 156: 44-56. DOI: 10.1001/jamadermatol.2019.3336
    [39]
    中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53: 81-88. https://www.cnki.com.cn/Article/CJFDTOTAL-LPFZ202005016.htm
    [40]
    Ruzicka T, Mihara R. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis[J]. N Engl J Med, 2017, 376: 2092-2093. DOI: 10.1056/NEJMc1704013
    [41]
    Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis[J]. JAKSTAT, 2013, 2: e24137.
    [42]
    Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80: 913-921. e9. DOI: 10.1016/j.jaad.2018.01.018
    [43]
    Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicen-tre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396: 255-266. DOI: 10.1016/S0140-6736(20)30732-7
    [44]
    Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145: 877-884. DOI: 10.1016/j.jaci.2019.11.025
    [45]
    Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies[J]. J Am Acad Dermatol, 2021, 85: 863-872. DOI: 10.1016/j.jaad.2021.04.085
    [46]
    Ciaravino V, Coronado D, Lanphear C, et al. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis[J]. J Dermatol Sci, 2017, 87: 116-122. DOI: 10.1016/j.jdermsci.2017.03.020
    [47]
    Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019, 11: eaax2945. DOI: 10.1126/scitranslmed.aax2945
    [48]
    黄世杰. 依托吉单抗治疗中重度特应性皮炎未能达到主终点[J]. 国际药学研究杂志, 2020, 47: 402. https://www.cnki.com.cn/Article/CJFDTOTAL-GWYZ202005014.htm
    [49]
    Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial[J]. J Am Acad Dermatol, 2019, 80: 1013-1021. DOI: 10.1016/j.jaad.2018.11.059
  • Related Articles

    [1]WANG Jun, MENG Juan. Targeted Therapy for Rheumatoid Arthritis in the New Era[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 19-27. DOI: 10.12290/xhyxzz.2024-0842
    [2]YANG Xiaoxi, TIAN Xinping, LI Mengtao, LENG Xiaomei, ZHAO Yan, ZENG Xiaofeng. Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 58-67. DOI: 10.12290/xhyxzz.2023-0391
    [3]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [4]LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. DOI: 10.3969/j.issn.1674-9081.2020.00.019
    [5]Hua-xia YANG, Feng-chun ZHANG. New Biologic Targets for Systemic Lupus Erythematosus: Hope and Challenge[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 241-246. DOI: 10.3969/j.issn.1674-9081.20200091
    [6]Cheng-mei HE, Feng-chun ZHANG. Belimumab:A New Targeted Drug for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 130-134. DOI: 10.3969/j.issn.1674-9081.20190114
    [7]He-wen TANG, Meng YANG, Yu-xin JIANG. Molecular Contrast Agents for Photoacoustic Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 358-363. DOI: 10.3969/j.issn.1674-9081.2018.04.013
    [8]Su-jie ZHANG, Hua-qi YIN, Xiong-jun YE, Tao XU. Role of Musashi-2 in the Occurrence and Development and as the Diagnostic and Therapeutic Target of Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 289-293. DOI: 10.3969/j.issn.1674-9081.2017.05.018
    [9]Zhao-jing XUE, Le SHEN, Zhi-yao WANG, Yu-guang HUANG. Feasibility of Signal Transducers and Activators of Transcription 3 Inhibitor WP1066 as a Novel Target for Neuropathic Pain[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(2): 142-147. DOI: 10.3969/j.issn.1674-9081.2014.02.003
    [10]Liang ZHU, Jian LIU, Jing LEI, Hai-yan XU, Jie MENG, Yong-lan HE, Zheng-yu JIN, Hua-dan XUE. Development of a Peptide-based Cancer-specific Magnetic Resonance Contrast Agent Targeting CXCR4 and Validation of Its Effects in Three Cancer Cell Lines[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(3): 286-293. DOI: 10.3969/j.issn.1674-9081.2013.03.014
  • Cited by

    Periodical cited type(10)

    1. 和增萍,廖承成,杨月皎,郭媛媛,赵悦,杨洋. 度普利尤单抗治疗31例中重度特应性皮炎的临床疗效及安全性. 中国医师杂志. 2024(01): 117-120 .
    2. 李晨,陈达灿,莫秀梅,陈艳婷,郭海媚,陈秀华. 岭南刺络放血疗法在特应性皮炎中的应用. 世界中医药. 2024(01): 43-46 .
    3. 王言之,田曼. 儿童过敏中瘙痒评估的方法学研究进展. 现代医学. 2024(06): 980-984 .
    4. 徐爽,蒋裕雄,高芸璐,于晓丽,朱晓萍. 瘙痒和睡眠质量对成人中重度特应性皮炎患者生活质量的影响. 中国中西医结合皮肤性病学杂志. 2024(04): 300-304 .
    5. 张鑫,付莲英,张艳晖,陈平. 虎符铜砭循经刮痧治疗小儿心脾积热型特应性皮炎疗效观察. 广西中医药. 2024(05): 20-23 .
    6. 董乾,郑瑞,何吉吉,郗月. 特应性皮炎瘙痒发病机制的研究进展. 皮肤科学通报. 2024(06): 695-700 .
    7. 刘水清,宋雪,陆东亚,刘小奇,费莎妮,韩梅,徐国梅. 阿布昔替尼治疗中重度特应性皮炎疗效与安全性的系统评价与meta分析. 重庆医学. 2023(10): 1545-1550 .
    8. 燕红霞,花日,贾秀娟,王百灵,高志清,张小峰,吴凤兰,木其日. TRPV1在特应性皮炎发病机制和治疗中的研究进展. 中国麻风皮肤病杂志. 2023(10): 770-773 .
    9. 张曾燕,张汇源,关建华,陈云龙. 黄连解毒汤改善1-氯-2, 4-二硝基苯诱导特应性皮炎小鼠瘙痒症状的作用及机制研究. 中药新药与临床药理. 2023(12): 1713-1720 .
    10. 王静梅,李荣,冯先虎,代菊高,刘亮. 新型JAK1抑制剂abrocitinib治疗青少年及成人中重度特应性皮炎的疗效及安全性的Meta分析. 中国临床药学杂志. 2023(11): 836-845 .

    Other cited types(9)

Catalog

    Article Metrics

    Article views (2747) PDF downloads (304) Cited by(19)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close